RS
NGNE icon

R Squared’s Neurogene NGNE Stock Holding History

R Squared’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-290
Closed -$6.63K – 1060
2024
Q4 		$6.63K Buy
+290
New +$10.8K 0.01% 1258

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

R Squared's NGNE Position: Q1 2025 in Review

R Squared sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 290 shares — an estimated $6.63K sold.

R Squared first reported a position in NGNE in Q4 2024 and held it in 1 quarter. The position peaked at $6.63K in Q4 2024. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • R Squared reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 290 Neurogene shares in Q1 2025, an estimated $6.63K.
  • R Squared first reported a position in Neurogene in Q4 2024 and held it in 1 quarter.
  • R Squared's Neurogene position peaked at $6.63K in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.